Recruiting
Phase 2

Modzatinib

Sponsor:

Aclaris Therapeutics, Inc.

Code:

NCT07935590

Conditions

Lichen Planus

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Modzatinib

Placebo

Study Details

Brief summary:

This study evaluates modzatinib versus placebo in participants with biopsy-proven forms of moderate-to-severe lichen planus (LP).

Conditions

Lichen Planus

Study ID

NCT07935590

Start date

Nov, 2026

Status verified date

Nov, 2026

Completion date

Apr, 2029

Anticipated

Primary completion date

Mar, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Key Inclusion Criteria:

  • Participants must have biopsy-confirmed OLP, CLP, or LPP eligible for systemic therapy and a history of inadequate response to topical corticosteroids (TCS) of high or ultra-high potency (based on the World Health Organization \[WHO\] definition) for at least 4 weeks in the opinion of the Investigator.

Specific criteria for each subtype below:

  • OLP: OLP IGA of ≥ 3 (moderate or severe) and either Baseline LP-related Pain or Burning Sensation NRS ≥ 3.
  • CLP: CLP IGA ≥3 (moderate or severe) and Baseline LP-related Itch NRS ≥ 3.
  • LPP: LPP IGA ≥ 3 (moderate or severe) and either Baseline LP-related Itch or Burning Sensation NRS ≥ 3.
  • If using any of the permitted treatments (that is, topical treatments on the affected areas, oral pain medications, and systemic antihistamines), the dose and frequency should remain stable for at least 2 weeks prior to randomization (Day 1) and until Week 16 (OLP and CLP cohorts) or Week 24 (LPP cohort).
  • Participant has a stable disease for at least 4 weeks prior to screening visit based on Investigator judgement.
  • Participant must be willing and able to comply with all study procedures and must be available for the duration of the study.

Key Exclusion Criteria:

  • Clinical history suspicious for and/or biopsy consistent with lichenoid drug eruption.
  • History or diagnosed LP other than OLP, CLP, or LPP (for example, lichen planus pigmentosus, paraneoplastic mucosal lichen planus, hypertrophic lichen planus, as well as actinic, inverse, linear, or bullous variants).
  • Participants with dysplastic changes in oral biopsy results.
  • Participant has any clinically significant medical condition, other skin conditions (including skin, scalp or mucosa infections), or physical/laboratory/electrocardiogram (ECG)/vital signs abnormality that would, in the opinion of the investigator, put the participant at undue risk or interfere with the study assessments.
  • Participant has any condition that could interfere with drug absorption including, but not limited to, short bowel syndrome, gastric bypass surgery (including sleeve gastrectomy). Participants with a history of gastric banding/segmentation are not to be excluded.
  • Participant has a known or suspected allergy to modzatinib or any component of the investigational product.
  • Participant is a female who is breastfeeding, pregnant, or who is planning to become pregnant during the study.

Note: Other protocol-defined inclusion and exclusion criteria may apply.

Study Design

Enrollment

102 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Oral Erosive Lichen Planus (OLP) Cohort

Participants will receive modzatinib or placebo administered orally twice daily (BID) for 16 weeks.

experimental: Cutaneous Lichen Planus (CLP) Cohort

Participants will receive modzatinib or placebo administered orally BID for 16 weeks.

experimental: Lichen Planopilaris (LPP) Cohort

Participants will receive modzatinib or placebo administered orally BID for 24 weeks.

Interventions

Modzatinib

Oral tablets

Placebo

Oral tablets

Primary outcome measure

  • Participants With OLP: Change From Baseline in Activity Score of the Oral Disease Severity Score (ODSS) at Week 16 [ Time Frame: Baseline, Week 16 ]
  • Participants With CLP: Change From Baseline in Modified Lichen Planus Area and Severity Index (LPASI) Score at Week 16 [ Time Frame: Baseline, Week 16 ]
  • Participants With LPP: Change From Baseline in Lichen Planopilaris Activity Index (LPPAI) Score at Week 24 [ Time Frame: Baseline, Week 24 ]

Central Contacts and Locations

Central contacts

Aclaris Clinical Operations

(484) 324-7933clintrials@aclaristx.com

Locations

Aclaris Clinical Site

Recruiting

Savannah, Georgia, United States, 31419

Contacts

Aclaris Clinical Operations

clintrials@aclaristx.com

More Information

Sponsor

Aclaris Therapeutics, Inc.

Last update posted

Nov 18, 2026

Last verified

Nov, 2026

Keywords

  • Biopsy-Proven Forms of Lichen Planus
  • Lichen Planus
  • OLP
  • CLP
  • LPP
  • LP
  • Oral Lichen Planus
  • Cutaneous Lichen Planus
  • Lichen Planopilaris

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-19. This information was provided to ClinicalTrials.gov by Aclaris Therapeutics, Inc. on 2026-11-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.